Skip to main content

Conference Correspondent

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Changes in Clinical Stage Identify Different Response Categories Among Patients in iwCLL PR: Analysis of CLL Patients on the RESONATE Study

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients

3
4
5
6
7
8

Page 6 of 8
Results 51 - 60 of 80